BeiGene, Ltd. , a drug company developing immuno-oncology drugs for cancer treatments, opened at $28.97 Thursday, above its initial public offering issue price of $24 and marked the first IPO of 2016. Shares were trading at $28.38. BeiGene sold 6.6 million shares at an issue price of $24, to raise about $158 million. The company initially set a price range between $22 and $24. Goldman, Sachs & Co., Morgan Stanley and Cowen and Company were the underwriters for the offering.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News